We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Par Pharmaceutical’s efforts to litigate its way to a generic version of Adderall XR ended with a whimper Nov. 24, after a federal judge barred the company from challenging Shire’s patents. Read More
Teva Pharmaceuticals is trying to divest assets in anticipation of regulatory objections to its purchase of Allergan’s generics division, according to a corporate filing. Read More
An international aid group has negotiated a multi-year licensing agreement with Bristol-Myers Squibb to produce generic hepatitis C medicines in many developing nations. Read More
The nation’s largest pharmacy benefits manager is throwing its support behind a cheaper alternative to Turing Pharmaceuticals’ expensive toxoplasmosis/HIV treatment, threatening its monopoly on the market. Read More
In a win for branded drugmakers, President Barack Obama signed into law a bill extending the exclusivity periods for many new drugs and biologics. The measure — H.R. 639, referred to as the “Improving Regulatory Transparency for New Medical Therapies Act” — was signed into law Nov. 25, congressional records show. Read More
Teva Pharmaceuticals is getting ready to divest assets in anticipation of regulatory objections to its purchase of Allergan’s generics division, according to a corporate filing. Read More
Amid increased scrutiny over drug pricing, Mylan has been hit with a subpoena from the antitrust division of the Department of Justice over pricing of its 50-year-old antibiotic doxycycline, the drugmaker revealed in an SEC filing. Read More